Pharmaceuticals & Therapeutics

The biotech firm's stock surged after announcing a massive share repurchase, a bold move balancing shareholder value with its high-stakes R&D pipeline.

Celebrating its first anniversary, this derm-founded brand is swapping viral trends for sustainable growth, community building, and a new scholarship.

Colorectal cancer is the #1 cancer killer for adults under 50. A new study reveals a shocking awareness gap that is fueling this growing public health crisis.

As Canada prepares for generic Semaglutide, U.S. patients look north for relief from soaring drug costs, navigating a complex web of savings and risks.

With U.S. cancer centers tripling adoption of its targeted drug delivery device, RenovoRx signals a potential shift in treating solid tumors.

On Rare Disease Day, Polaryx Therapeutics advances a novel oral drug in a pivotal trial for four devastating pediatric disorders, offering a new strategy.

After securing its Nasdaq spot, TuHURA Biosciences shifts focus to its promising immuno-oncology pipeline, aiming to tackle cancer treatment resistance.

A key European panel recommends Dupixent for children with chronic hives, offering a potential first-of-its-kind targeted therapy for a difficult condition.

A high-stakes legal battle unfolds as Xeris sues to block generic versions of its blockbuster Cushing's syndrome drug, Recorlev, until 2040.

Tectonic Therapeutic reports key clinical progress in two distinct rare diseases, backed by a strong cash position and new leadership for its next phase.

Structure Therapeutics reports strong Phase 2 data for its oral obesity pill, aleniglipron, positioning it as a key contender in the race for pill-based GLP-1s.

The 3M spin-off navigates a transformative year, posting strong organic growth driven by MedSurg and Dental, despite a reported sales dip from divestitures.

With Phase 3 epilepsy results for its lead drug azetukalner due in March, Xenon reveals a major R&D spend and a cash runway to fuel its broad pipeline.

With clinical results converging, a new report reveals the real GLP-1 battle is fought in patent filings, not labs, deciding who wins this $100B+ market.

Biotech giant Regeneron extends its sponsorship of America's top high school science contest, securing its legacy and boosting access for a new generation.

A key partnership ensures the supply of a breakthrough therapy for FOP, a devastating condition where muscle turns to bone, highlighting a new era in drug production.

With promising data for its oral STAT6 degrader and a cash runway into 2029, Kymera Therapeutics is poised to disrupt the injectable-dominated market.

Kairos Pharma aims to reshape lung cancer treatment by acquiring two AI-designed drugs, targeting a key resistance mechanism in a multi-billion dollar market.

With a key FDA decision looming and pivotal data on a second therapy imminent, Viridian is poised to reshape the multi-billion dollar Thyroid Eye Disease market.

As colorectal cancer rates rise in younger adults, advocates demand provinces lower the screening age. But will policymakers act on the growing evidence?